Healthcare and Economic Burden of Intravenous and Subcutaneous Immunoglobulin Treatment in Three Autoimmune Neuromuscular Diseases: A Bicentric Spanish Experience
Author(s)
Ana Hernando, RN1, Jose M Cabrera-Maqueda, MD1, Eugenia Martinez-Hernandez, MD1, Cristina González-Mingot, MD2, Silvia Peralta-Moncusi, RN2, Mariajosé Solana Moga, RN2, Maria Soler, MSc3, Daniel Pérez-Troncoso, PhD3, Jenny Álvarez Nieto, MD, PhD4, Laura Vidal Barrientos, MSc4.
1Department of Neurology, Hospital Clinic of Barcelona, Barcelona, Spain, 2Hospital Arnau de Vilanova, Lleida, Spain, 3Outcomes'10 (A ProductLife Group Company), Castellón de la Plana, Spain, 4CSL Behring, Barcelona, Spain.
1Department of Neurology, Hospital Clinic of Barcelona, Barcelona, Spain, 2Hospital Arnau de Vilanova, Lleida, Spain, 3Outcomes'10 (A ProductLife Group Company), Castellón de la Plana, Spain, 4CSL Behring, Barcelona, Spain.
OBJECTIVES: Intravenous immunoglobulin (IVIG) is recommended by both European and Spanish clinical guidelines for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and myasthenia gravis (MG). Subcutaneous immunoglobulin (SCIG) is gaining interest due to home self-administration, a favorable safety profile, and potential cost savings. However, real-world evidence on healthcare resource utilization and associated costs remains limited. This study aims to compare healthcare resource consumption and total treatment costs of SCIG versus IVIG in patients with CIDP, MMN and MG treated at two tertiary hospitals in Spain.
METHODS: We collected aggregated data from two hospital-based cohorts of patients treated sequentially with IVIG followed by SCIG. The analysis focused on quantifying resource use to calculate health care costs from the Spanish National Health System (NHS) perspective. Cost components included drug acquisition and administration, adverse events, patient education, and clinical follow-up. These were annualized to estimate the total cost per patient-year for each treatment modality, enabling direct comparison.
RESULTS: Fourteen patients were included (7 from Hospital Clínic of Barcelona, and 7 from Hospital Arnau de Vilanova, Lleida), with a mean (standard deviation [SD]) age of 66.72 (15.13) years; 50% (n=7) were women. In terms of diagnosis, 57.14% (n=8) had CIDP, 28.57 % (n=4) MMN, and 14.29 % (n=2) MG. The mean (SD) follow-up duration was 80.5 (46.54) months while receiving IVIG and 25.5 (20.96) months while receiving SCIG. During treatment with SCIG, the number of annual hospital visits was reduced to 7.25, compared to 27.90 with IVIG. All resource consumption was measured using Spanish health-care unit costs.
CONCLUSIONS: This bicentric analysis will provide real-world comparative data on the cost of IVIG and SCIG from the Spanish National Health System perspective, offering context-specific evidence and enriching the current landscape of health-economic research in immune-mediated neuromuscular disorders.
METHODS: We collected aggregated data from two hospital-based cohorts of patients treated sequentially with IVIG followed by SCIG. The analysis focused on quantifying resource use to calculate health care costs from the Spanish National Health System (NHS) perspective. Cost components included drug acquisition and administration, adverse events, patient education, and clinical follow-up. These were annualized to estimate the total cost per patient-year for each treatment modality, enabling direct comparison.
RESULTS: Fourteen patients were included (7 from Hospital Clínic of Barcelona, and 7 from Hospital Arnau de Vilanova, Lleida), with a mean (standard deviation [SD]) age of 66.72 (15.13) years; 50% (n=7) were women. In terms of diagnosis, 57.14% (n=8) had CIDP, 28.57 % (n=4) MMN, and 14.29 % (n=2) MG. The mean (SD) follow-up duration was 80.5 (46.54) months while receiving IVIG and 25.5 (20.96) months while receiving SCIG. During treatment with SCIG, the number of annual hospital visits was reduced to 7.25, compared to 27.90 with IVIG. All resource consumption was measured using Spanish health-care unit costs.
CONCLUSIONS: This bicentric analysis will provide real-world comparative data on the cost of IVIG and SCIG from the Spanish National Health System perspective, offering context-specific evidence and enriching the current landscape of health-economic research in immune-mediated neuromuscular disorders.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE496
Topic
Economic Evaluation, Real World Data & Information Systems
Disease
Neurological Disorders